Perspectives on Managing Moderate-to-Severe Atopic Dermatitis

Drs. April Armstrong, Lawrence Eichenfield & Adam Friedman

The Ps of Lichen Planus got nothing on this alliteration filled podcast that was purposefully positioned to perfect your practice prowess to punish the pruritus and picking of AD. Join host Dr. Adam Friedman in part four of five of this Atopic Dermatitis dedicated series as he parties with and picks the brains of dermatology powerhouses Dr.s April Armstrong and Lawrence Eichenfield on pursuing a practical and powerful process to partner with patients of all ages and partake in a long standing management strategy. Please do not push this one off – I promise it is educational perfection. (That’s 24 Ps!)

Upon completion of this podcast participants should be able to:

  • Discuss management strategies for patients with moderate-to-severe atopic dermatitis
  • Identify common co-morbidities of atopic dermatitis and strategies for optimal patient care

This podcast is supported by an independent medical education grant provided by Sanofi Genzyme & Regeneron Pharmaceuticals.

Disclosures
April W. Armstrong, MD, MPH – No disclosures.

Lawrence F. Eichenfield, MD – Grant/Research Support: Abbvie, Pfizer, Regeneron, Sanofi-Genzyme, Ortho Derm, Verrica. Consultant: Almirall, Arcutis, Asana, Dermavant, Dermira, Forte, Galderma, Incyte, Leo Pharma, Lilly, Novartis, OrthoDerm. Speakers’ Bureau: Pfizer, Regeneron, Sanofi-Genzyme.

Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.